Current Hepatitis Reports

, Volume 4, Issue 3, pp 97–103 | Cite as

Advances in the treatment of hepatitis C in children and adolescents

  • Valérie A. McLin
  • William F. Balistreri
Article

Abstract

Progress is being made in the treatment of hepatitis C virus (HCV) infection in adults. The current recommended strategy is to use the combination of pegylated-interferon and ribavirin, which leads to a sustained virologic response rate in 50% to 60% of individuals eligible for treatment. Less is known about HCV infection in the pediatric population. Recently, small and uncontrolled studies have suggested that combination therapy of interferon alpha with ribavirin improves the outcome of HCV-infected children. There are no data yet regarding the use of pegylated interferons in pediatrics. This article summarizes what is known about the treatment of HCV in children and adolescents, and discusses future areas of research as they may pertain to the idiosyncrasies of the pediatric population.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    United States National Institute of Diabetes & Digestive & Kidney Diseases: NIH Action Plan for Liver Disease Research. http://www.niddk.nih.gov/fund/divisions/ddn/ldrb/ldrb_action_plan.htm. Accessed February 20, 2005.Google Scholar
  2. 2.
    Jara P, Resti M, Hierro L, et al.: Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003, 36:275–280.PubMedCrossRefGoogle Scholar
  3. 3.
    Hochman JA, Balistreri WF: Chronic viral hepatitis: always be current! Pediatr Rev 2003, 24:399–410.PubMedGoogle Scholar
  4. 4.
    Bortolotti F, Jara P, Diaz C, et al.: Posttransfusion and communityacquired hepatitis C in childhood. J Pediatr Gastroenterol Nutr 1994, 18:279–283.PubMedCrossRefGoogle Scholar
  5. 5.
    Vogt M, Lang T, Frosner G, et al.: Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood donor screening. N Engl J Med 1999, 341:866–870.PubMedCrossRefGoogle Scholar
  6. 6.
    Casiraghi M, De Paschale M, Romanò L, et al.: Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions given at birth. Hepatology 2004, 39:90–96.PubMedCrossRefGoogle Scholar
  7. 7.
    Guido M, Bortolotti F, Leandro G, et al.: Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? Am J Gastroenterol 2003, 98:660–663.PubMedCrossRefGoogle Scholar
  8. 8.
    Rerksuppaphol S, Hardikar W, Dore GJ: Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. J Gastroenterol Hepatol 2004, 19:1357–1362.PubMedCrossRefGoogle Scholar
  9. 9.
    Sinha M, Das A: Cost-effectiveness analysis of different strategies of management of chronic hepatitis C infection in children. Pediatr Infect Dis J 2000, 19:23–30.PubMedCrossRefGoogle Scholar
  10. 10.
    Gonzalez-Peralta RP: Treatment of chronic hepatitis C in children. Pediatr Transplant 2004, 8:639–643. Excellent review of treatment modalities and results to date.PubMedCrossRefGoogle Scholar
  11. 11.
    Jacobson KR, Murray K, Zellos A, Schwarz KB: An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastorenterol Nutr 2002, 34:52–58.CrossRefGoogle Scholar
  12. 12.
    Carithers RI, Emerson SS: Therapy of hepatitis C: metaanalysis of interferon alfa-2b trials. Hepatology 1997, 26(suppl):83S-88S.PubMedCrossRefGoogle Scholar
  13. 13.
    McHutchinson JG, Gordon SC, Schiff ER, et al.: Interferon alpha 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis C Interventional Therapy Group. N Engl J Med 1998, 339:1485–1492.CrossRefGoogle Scholar
  14. 14.
    Brillanti S, Miglioli M, Barbara L: Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J Hepatol 1995, 23(suppl 2):13–15; discussion 15–16.PubMedGoogle Scholar
  15. 15.
    Kelly D, Bunn S, Apelian D, et al.: Safety, efficacy, and pharmacokinetics of interferon alfa-2b plus ribavirin in children with chronic hepatitis C. Hepatology 2001, 34:680A.Google Scholar
  16. 16.
    Wirth S, Lang T, Ghering S, Gerner P: Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002, 36:1280–1284.PubMedCrossRefGoogle Scholar
  17. 17.
    Christensson B, Wiebe T, Akesson A, Widell A: Interferonalpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis 2000, 30:585–586.PubMedCrossRefGoogle Scholar
  18. 18.
    Lackner H, Moser A, Deutsch J, et al.: Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics 2000, 106:E53.PubMedCrossRefGoogle Scholar
  19. 19.
    Suoglu OD, Elkabes B, Sokucu S, Saner G: Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C? J Pediatr Gastroenterol Nutr 2002, 34:199–206.CrossRefGoogle Scholar
  20. 20.
    Hartman C, Berkowitz D, Rimon N, Shamir R: The effect of early treatment in children with chronic hepatitis. J Pediatr Gastroenterol Nutr 2003, 37:252–257.PubMedCrossRefGoogle Scholar
  21. 21.
    Schwarz KB, Mohan P, Narkewicz M, et al.: The safety, efficacy and pharmacokinetics of peginterferon alfa-2a (40 kD) in children with chronic hepatitis C. Gastroenterology 2003, 124:A700.CrossRefGoogle Scholar
  22. 22.
    Hoofnagle JH: Peds-C. Hepatology 2005, 41:421.PubMedCrossRefGoogle Scholar
  23. 23.
    Li DY, Schwarz KB: Immunopathogenesis of chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2002, 35:260–267.PubMedCrossRefGoogle Scholar
  24. 24.
    Strader DB, Wright T, Thomas DL, et al.: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147–1171.PubMedCrossRefGoogle Scholar
  25. 25.
    Scotto G, Palumbo E, Fazio V: Peginterferon alfa-2b treatment for patients affected by acute hepatitis C: presentation of six case reports. Infection 2005, 33:30–32.PubMedCrossRefGoogle Scholar
  26. 26.
    Nowicki MJ, Ahmad N, Heubi J, et al.: The prevalence of hepatitis C virus (HCV) in infants and children after liver transplantation. Dig Dis Sci 1994, 39:2250–2254.PubMedCrossRefGoogle Scholar
  27. 27.
    McDiarmid SV, Conrad A, Ament ME, et al.: De novo hepatitis C in children after liver transplantation. Transplantation 1998, 66:311–318.PubMedCrossRefGoogle Scholar
  28. 28.
    Barlow CF, Priebe CJ, Mulliken JB, et al.: Spastic diplegia as a complication of interferon alfa2a treatment of hemangiomas in infancy. J Pediatr 1998, 132:527–530.PubMedCrossRefGoogle Scholar
  29. 29.
    Hardikar W: Hepatitis C in childhood. J Gastroenterol Hepatol 2002, 17:476–481.PubMedCrossRefGoogle Scholar
  30. 30.
    Mofenson LM, Oleske J, Serchuck L, et al.: Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. Clin Infect Dis 2005, 40(suppl 1):S1-S84.PubMedCrossRefGoogle Scholar
  31. 31.
    Iorio R, Pensati P, Botta S, et al.: Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J 1997, 16:984–990.PubMedCrossRefGoogle Scholar
  32. 32.
    Martinot-Peignoux M, Boyer N, Pouteau M, et al.: Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998, 29:214–223.PubMedCrossRefGoogle Scholar
  33. 33.
    National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C [no authors listed]. Hepatology. 1997, 26:2S–10S.Google Scholar
  34. 34.
    Murray KF, Richardson LP, Morishima C, et al.: Prevalence of hepatitis C infection and risk factors in an incarcerated juvenile population: a pilot study. Pediatrics 2003, 111:153–157.PubMedCrossRefGoogle Scholar
  35. 35.
    Hugle T, Cerny A: Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. Rev Med Virol 2003, 13:361–371. Review of ongoing areas of research in the field of hepatitis C treatment.PubMedCrossRefGoogle Scholar
  36. 36.
    Rockey DC: Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol 2005, 3:95–107.PubMedCrossRefGoogle Scholar
  37. 37.
    Delgado-Borrego A, Jonas MM: Treatment options for hepatitis C infection in children. Curr Treat Options Gastroenterol 2004, 7:373–379. Practical guide to the management of pediatric hepatitis C according to the U.S. Food and Drug Administration guidelines combining IFN alpha with ribavirin.PubMedGoogle Scholar
  38. 38.
    Hepatitis C. In Red Book Online. Edited by Pickering, LK. Elk Grove Village, IL: American Academy of Pediatrics; 2003: 336–340. http://aapredbook.aappublications.org/cgi/content/full/2003/1/3.52Google Scholar
  39. 39.
    Gibb DM, Goodall RL, Dunn DT, et al.: Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000, 356:904–907.PubMedCrossRefGoogle Scholar
  40. 40.
    Steininger C, Kundi M, Jatzko G, et al.: Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. J Infect Dis 2003, 187:345–351.PubMedCrossRefGoogle Scholar
  41. 41.
    Okamoto M, Nagata I, Murakami J, et al.: Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high virus load, vaginal delivery, and negative anti-NS4 antibody. J Infect Dis 2000, 182:1511–1514.PubMedCrossRefGoogle Scholar
  42. 42.
    Mast EE: Mother-to-infant hepatitis C virus transmission and breastfeeding. Adv Exp Med Biol 2004, 554:211–216.PubMedGoogle Scholar
  43. 43.
    Hickman IJ, Powell EE, Prins JB, et al.: In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003, 39:1042–1048.PubMedCrossRefGoogle Scholar
  44. 44.
    Hourigan LF, Macdonald GA, Purdie D, et al.: Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999, 29:1215–1219.PubMedCrossRefGoogle Scholar
  45. 45.
    Thomopoulos KC, Theocharis GJ, Tsamantas AC, et al.: Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2005, 17:149–153.PubMedCrossRefGoogle Scholar
  46. 46.
    Bruno R, Sacchi P, Maiocchi L, et al.: Host factors affecting the outcome of treatment of hepatitis C. Rev Gastroenterol Disord 2004, 4(suppl 1):S3-S7.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Valérie A. McLin
    • 1
  • William F. Balistreri
  1. 1.Division of Gastroenterology, Hepatology, and NutritionCincinnati Children’s Hospital Medical CenterCincinnatiUSA

Personalised recommendations